[biophysboy]

To give a more financial answer, it’s because pharma products have a low probability of success and have long lag times. That means a high cost of capital: lenders and investors are going to expect good returns to make up for the risk.

Second, biotech/pharma actually already do invest quite a lot in R&D. But they tend to focus on translational work rather than speculative exploration, because it is less risky.